PubRank

L H Price

Author PubWeight™ 173.22‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989 16.61
2 The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 1989 6.80
3 Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990 3.57
4 A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000 2.48
5 Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N Engl J Med 1992 2.39
6 Clinical phenomenology and neurobiology of cocaine abstinence: a prospective inpatient study. Am J Psychiatry 1991 2.17
7 A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996 2.04
8 Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects. Am J Psychiatry 1994 2.04
9 Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry 1998 2.03
10 Efficacy of continuation ECT and antidepressant drugs compared to long-term antidepressants alone in depressed patients. Am J Psychiatry 2000 1.94
11 Family accommodation in obsessive-compulsive disorder. Am J Psychiatry 1995 1.84
12 Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry 1989 1.66
13 Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 1990 1.56
14 Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994 1.56
15 Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry 1997 1.54
16 Family accommodation of obsessive-compulsive symptoms: instrument development and assessment of family behavior. J Nerv Ment Dis 1999 1.52
17 Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry 1995 1.52
18 Tryptophan depletion during continuous CSF sampling in healthy human subjects. Neuropsychopharmacology 1998 1.51
19 Clomipramine in autism: preliminary evidence of efficacy. J Am Acad Child Adolesc Psychiatry 1992 1.49
20 Serotonergic dysfunction in depression associated with Parkinson's disease. Neurology 1992 1.48
21 A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 1998 1.47
22 A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol 1991 1.45
23 A haplotype at the DBH locus, associated with low plasma dopamine beta-hydroxylase activity, also associates with cocaine-induced paranoia. Mol Psychiatry 2000 1.44
24 Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatry 1996 1.41
25 Rapid detoxification from opioid dependence. Am J Psychiatry 1989 1.40
26 A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. Am J Psychiatry 1995 1.27
27 Noradrenergic dysregulation during discontinuation of cocaine use in addicts. Arch Gen Psychiatry 1994 1.22
28 Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I] beta-CIT SPECT. Am J Psychiatry 1998 1.19
29 Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1990 1.17
30 Dopamine beta-hydroxylase: two polymorphisms in linkage disequilibrium at the structural gene DBH associate with biochemical phenotypic variation. Hum Genet 1998 1.16
31 Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry 1994 1.16
32 Concurrent cocaine-ethanol ingestion in humans: pharmacology, physiology, behavior, and the role of cocaethylene. Psychopharmacology (Berl) 1993 1.15
33 Elevated cerebrospinal fluid levels of oxytocin in obsessive-compulsive disorder. Comparison with Tourette's syndrome and healthy controls. Arch Gen Psychiatry 1994 1.14
34 Gender differences in response to intranasal cocaine administration to humans. Biol Psychiatry 1996 1.13
35 Behavioral, physiological, and pharmacological interaction of cocaine and disulfiram in humans. Biol Psychiatry 1995 1.13
36 Cocaethylene: pharmacology, physiology and behavioral effects in humans. J Pharmacol Exp Ther 1995 1.12
37 Insight and treatment outcome in obsessive-compulsive disorder. Compr Psychiatry 2001 1.10
38 Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse. Arch Gen Psychiatry 1997 1.08
39 Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? J Clin Psychiatry 1990 1.08
40 Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder. Mol Psychiatry 1998 1.05
41 Intranasal oxytocin in obsessive-compulsive disorder. Biol Psychiatry 1996 1.03
42 [123I]beta-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. Am J Psychiatry 1995 1.03
43 Three cases of manic symptoms following yohimbine administration. Am J Psychiatry 1984 1.03
44 Genetic polymorphism at the CLOCK gene locus and major depression. Am J Med Genet 2000 1.02
45 Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation. J Child Adolesc Psychopharmacol 1997 1.01
46 The neurobiological correlates of childhood adversity and implications for treatment. Acta Psychiatr Scand 2013 1.01
47 The role of central oxytocin in obsessive compulsive disorder and related normal behavior. Psychoneuroendocrinology 1994 0.98
48 A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology (Berl) 1992 0.97
49 Global functioning of inpatients with obsessive-compulsive disorder, schizophrenia, and major depression. Psychiatr Serv 1998 0.96
50 The serotonin hypothesis of obsessive compulsive disorder: implications of pharmacologic challenge studies. J Clin Psychiatry 1992 0.95
51 Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function? Am J Drug Alcohol Abuse 1992 0.95
52 Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J Clin Psychopharmacol 1998 0.95
53 Assessment of severity and change in obsessive compulsive disorder. Psychiatr Clin North Am 1992 0.92
54 Opioid antagonist challenges in buprenorphine maintained patients. Drug Alcohol Depend 1990 0.91
55 Effects of acute tryptophan depletion on nocturnal melatonin secretion in humans. J Clin Endocrinol Metab 1993 0.91
56 Dextromethorphan-induced psychosis. Am J Psychiatry 2000 0.90
57 Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiatry 1988 0.90
58 Treatment of clozapine-induced parotid gland swelling. Am J Psychiatry 1996 0.90
59 Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression. Psychopharmacol Bull 1991 0.90
60 Temperament and response to the Trier Social Stress Test. Acta Psychiatr Scand 2007 0.89
61 Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 1999 0.89
62 Effects of fluoxetine administration on mood response to tryptophan depletion in healthy subjects. Biol Psychiatry 1997 0.89
63 The pharmacotherapy of obsessive-compulsive disorder. Pharmacopsychiatry 1993 0.89
64 The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder. J Clin Psychopharmacol 1993 0.88
65 Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry 1994 0.88
66 The psychopharmacology of obsessive compulsive disorder. Implications for treatment and pathogenesis. Psychiatr Clin North Am 1993 0.88
67 Exaggerated smooth muscle contraction segments on esophageal high-resolution manometry: prevalence and clinical relevance. Neurogastroenterol Motil 2014 0.87
68 Obsessive-compulsive disorder with and without a chronic tic disorder. A comparison of symptoms in 70 patients. Br J Psychiatry 1994 0.87
69 Neuroendocrine and behavioral effects of dietary tryptophan restriction in healthy subjects. Life Sci 1989 0.87
70 Reliability and validity of the symptoms of major depressive illness. Arch Gen Psychiatry 1986 0.87
71 Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder. J Clin Psychiatry 1994 0.86
72 Vagus nerve stimulation for depression: rationale, anatomical and physiological basis of efficacy and future prospects. Acta Neurochir Suppl 2007 0.86
73 Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry 1995 0.86
74 Regional cerebral blood flow during acute and chronic abstinence from combined cocaine-alcohol abuse. Drug Alcohol Depend 1998 0.85
75 Perceptual asymmetry differences between major depression with or without a comorbid anxiety disorder: a dichotic listening study. J Abnorm Psychol 1999 0.85
76 Biological approaches to treatment-resistant obsessive compulsive disorder. J Clin Psychiatry 1993 0.84
77 Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1993 0.84
78 Naltrexone augmentation of neuroleptics in schizophrenia. J Clin Psychopharmacol 1998 0.84
79 The serotonin hypothesis of obsessive compulsive disorder. Int Clin Psychopharmacol 1993 0.84
80 Clinical experience with mirtazapine in the treatment of panic disorder. Ann Clin Psychiatry 1999 0.84
81 Fluvoxamine/pimozide treatment of concurrent Tourette's and obsessive-compulsive disorder. Br J Psychiatry 1990 0.83
82 Reserpine augmentation of desipramine in refractory depression: clinical and neurobiological effects. Psychopharmacology (Berl) 1987 0.83
83 Variability of response to lithium augmentation in refractory depression. Am J Psychiatry 1986 0.83
84 Physical symptoms associated with paroxetine discontinuation. Am J Psychiatry 1994 0.83
85 Alpha 2-adrenergic receptor function in depression. The cortisol response to yohimbine. Arch Gen Psychiatry 1986 0.83
86 Mood stabilization and weight loss with topiramate. Am J Psychiatry 1999 0.83
87 Serotonergic mechanisms of cocaine effects in humans. Psychopharmacology (Berl) 1995 0.83
88 Antiglucocorticoid treatment of refractory depression with ketoconazole: a case report. Biol Psychiatry 1995 0.83
89 The role of serotonin and dopamine in the pathophysiology of obsessive compulsive disorder. Int Clin Psychopharmacol 1992 0.83
90 Effects of tryptophan depletion on responses to yohimbine in healthy human subjects. Biol Psychiatry 1995 0.82
91 Acute exacerbation of body dysmorphic disorder during tryptophan depletion. Am J Psychiatry 1992 0.82
92 Buprenorphine: duration of blockade of effects of intramuscular hydromorphone. Drug Alcohol Depend 1994 0.82
93 m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia. Arch Gen Psychiatry 1993 0.82
94 Euphorigenic doses of cocaine reduce [123I]beta-CIT SPECT measures of dopamine transporter availability in human cocaine addicts. Psychopharmacology (Berl) 1995 0.82
95 Multiple sclerosis presenting as major depression: a diagnosis suggested by MRI scan but not CT scan. J Clin Psychiatry 1988 0.81
96 m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation. Biol Psychiatry 1995 0.81
97 Acute tryptophan depletion in autistic disorder: a controlled case study. Biol Psychiatry 1993 0.81
98 Pharmacotherapy of obsessive compulsive disorder. J Clin Psychiatry 1992 0.81
99 C-reactive protein, early life stress, and wellbeing in healthy adults. Acta Psychiatr Scand 2012 0.81
100 Possible role of neuropeptides in obsessive compulsive disorder. Psychoneuroendocrinology 1999 0.81
101 Noradrenergic function and the cortisol response to dexamethasone in depression. Psychiatry Res 1985 0.81
102 Dopaminergic responsivity during cocaine abstinence: a pilot study. Psychiatry Res 1992 0.81
103 Serotonin syndrome. Am J Psychiatry 1992 0.80
104 SPECT regional cerebral blood flow and neuropsychological testing in non-demented HIV-positive drug abusers: preliminary results. Prog Neuropsychopharmacol Biol Psychiatry 1991 0.80
105 Noradrenergic response to acute ethanol administration in healthy subjects: comparison with intravenous yohimbine. Psychopharmacology (Berl) 1995 0.80
106 Desipramine-yohimbine combination treatment of refractory depression. Implications for the beta-adrenergic receptor hypothesis of antidepressant action. Arch Gen Psychiatry 1986 0.80
107 Altered response to neuroendocrine challenge linked to indices of the metabolic syndrome in healthy adults. Horm Metab Res 2012 0.80
108 Opiate dependence and withdrawal: preliminary assessment using single photon emission computerized tomography (SPECT). Am J Drug Alcohol Abuse 1995 0.79
109 Urinary 6-hydroxymelatonin sulfate as a measure of melatonin secretion during acute tryptophan depletion. Psychoneuroendocrinology 1993 0.79
110 [123I]beta-CIT SPECT imaging of dopamine transporter availability after mazindol administration in human cocaine addicts. Psychopharmacology (Berl) 1998 0.79
111 Psychotic depression: what is it and how should we treat it? Harv Rev Psychiatry 2000 0.78
112 Noradrenergic and serotonergic receptor system function in panic disorder and depression. Acta Psychiatr Scand Suppl 1988 0.78
113 Intranasal oxytocin in trichotillomania. Biol Psychiatry 1996 0.78
114 Pathophysiology of obsessive-compulsive disorder. Am J Psychiatry 1989 0.78
115 What is the duration for augmentation with T3 or lithium in resistant depression? J Clin Psychopharmacol 1989 0.78
116 Efficacy of lithium-tranylcypromine treatment in refractory depression. Am J Psychiatry 1985 0.78
117 Decreased perceptual sensitivity to emotion-evoking stimuli in depression. Psychiatry Res 1994 0.78
118 Adjunctive gabapentin in treatment-resistant depression: a retrospective chart review. J Affect Disord 2001 0.78
119 Dose-response relationship for oral idazoxan effects in healthy human subjects: comparison with oral yohimbine. Psychopharmacology (Berl) 1992 0.78
120 Depression associated with vitamin A intoxication. Psychosomatics 1992 0.78
121 Neuroleptic dose and desipramine concentrations during combined treatment of unipolar delusional depression. Am J Psychiatry 1986 0.77
122 Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Am J Psychiatry 1997 0.77
123 Assessment of diurnal variation of cerebrospinal fluid tryptophan and 5-hydroxyindoleacetic acid in healthy human females. Life Sci 1997 0.77
124 Lithium and desipramine versus desipramine alone in the treatment of severe major depression: a preliminary study. Int Clin Psychopharmacol 1998 0.77
125 Inpatient treatment of patients with severe obsessive-compulsive disorder. Hosp Community Psychiatry 1993 0.77
126 alpha 2-Adrenergic receptor sensitivity in depression. The plasma MHPG, behavioral, and cardiovascular responses to yohimbine. Arch Gen Psychiatry 1988 0.77
127 Treatment of severe obsessive-compulsive disorder with fluvoxamine. Am J Psychiatry 1987 0.77
128 Lithium augmentation of combined neuroleptic-tricyclic treatment in delusional depression. Am J Psychiatry 1983 0.77
129 After lithium augmentation: a retrospective follow-up of patients with antidepressant-refractory depression. J Affect Disord 1990 0.77
130 Paroxetine: a new serotonin reuptake inhibitor for the treatment of depression. Conn Med 1993 0.77
131 Effects of acute tryptophan depletion in lithium-remitted manic patients: a pilot study. Biol Psychiatry 1997 0.77
132 The use of antibody D8/17 to identify B cells in adults with obsessive-compulsive disorder. Psychiatry Res 2001 0.76
133 Effects of catecholamine depletion with AMPT (alpha-methyl-para-tyrosine) in obsessive-compulsive disorder. Biol Psychiatry 1999 0.76
134 Fluvoxamine treatment of coincident autistic disorder and obsessive-compulsive disorder: a case report. J Autism Dev Disord 1990 0.76
135 Desipramine-associated hepatitis. J Clin Psychopharmacol 1983 0.76
136 Limited efficacy of ketoconazole in treatment-refractory major depression. J Clin Psychopharmacol 1999 0.76
137 Serotonin transporter-blocking properties of nefazodone assessed by measurement of platelet serotonin. J Clin Psychopharmacol 1998 0.76
138 Risperidone addition in serotonin reuptake inhibitor-resistant trichotillomania: three cases. J Child Adolesc Psychopharmacol 1999 0.76
139 Yohimbine augmentation of fluvoxamine in refractory depression: a single-blind study. Biol Psychiatry 1995 0.76
140 Effects of tryptophan depletion in panic disorder. Biol Psychiatry 1994 0.76
141 Does the cholecystokinin antagonist proglumide possess antipsychotic activity? Psychiatry Res 1986 0.76
142 Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects. Psychiatry Res 1991 0.76
143 Effects of trazodone treatment on alpha-2 adrenoceptor function in depressed patients. Psychopharmacology (Berl) 1986 0.76
144 Family history in delusional depression. J Affect Disord 1984 0.76
145 Effects of tranylcypromine treatment on neuroendocrine, behavioral, and autonomic responses to tryptophan in depressed patients. Life Sci 1985 0.76
146 Efficacy of papaverine addition for treatment-refractory major depression. Am J Psychiatry 1997 0.76
147 A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder. Drug Saf 1996 0.75
148 Treating imagined ugliness. Arch Gen Psychiatry 1999 0.75
149 Effects of the CCK(B) antagonist CI-988 on responses to mCPP in generalized anxiety disorder. Psychiatry Res 1999 0.75
150 Cellular replacement of dopamine deficit in Parkinson's disease using human fetal mesencephalic tissue: preliminary results in four patients. Res Publ Assoc Res Nerv Ment Dis 1993 0.75
151 Lithium or desipramine augmentation of fluoxetine treatment. Am J Psychiatry 1995 0.75
152 Tryptophan-deficient diet and amino acid drink deplete plasma tryptophan and induce a relapse of depression in susceptible patients. J Chem Neuroanat 1992 0.75
153 Fluvoxamine as an antiobsessional agent. Psychopharmacol Bull 1989 0.75
154 Obsessive-compulsive symptoms with-neuroleptics. J Am Acad Child Adolesc Psychiatry 1996 0.75
155 Ineffectiveness of clonidine in the treatment of the benzodiazepine withdrawal syndrome: report of three cases. Am J Psychiatry 1986 0.75
156 Mania induced by lithium augmentation. Am J Psychiatry 1987 0.75
157 Effects of acute buprenorphine on responses to intranasal cocaine: a pilot study. Am J Drug Alcohol Abuse 1993 0.75
158 Stress and depression: is neuroimmunology the missing link? Harv Rev Psychiatry 1998 0.75
159 The clinical utility of family history for the diagnosis of melancholia. J Nerv Ment Dis 1984 0.75
160 Opening the mouth to abolish auditory hallucinations. Am J Psychiatry 1988 0.75
161 A preliminary study of tryptophan depletion on tics, obsessive-compulsive symptoms, and mood in Tourette's syndrome. Biol Psychiatry 1997 0.75
162 Seasonal variation in neuroendocrine and mood responses to i.v. L-tryptophan in depressed patients and healthy subjects. Neuropsychopharmacology 1996 0.75
163 Alcoholism and affective disorder. Am J Psychiatry 1986 0.75
164 Major depression and panic disorder: diagnostic and neurobiological relationships. Psychopharmacol Bull 1986 0.75
165 Rapid improvement of delusional depression following drug-induced seizures: case report. J Clin Psychiatry 1985 0.75
166 Effects of serotonergic agonists on neuroendocrine responses of rhesus monkeys and patients with depression and anxiety disorders. Psychopharmacol Ser 1989 0.75
167 Efficacy of fluvoxamine in treatment-refractory depression. J Affect Disord 1988 0.75
168 Manic symptoms following addition of lithium to antidepressant treatment. J Clin Psychopharmacol 1984 0.75
169 Can yohimbine be used to treat orthostatic hypotension associated with the use of desipramine and other antidepressants? What general and/or specific strategy do you recommend for treating orthostatic hypotension? J Clin Psychopharmacol 1988 0.75
170 Ciliary neurotrophic factor null allele frequencies in schizophrenia, affective disorders, and Alzheimer's disease. Am J Med Genet 1997 0.75
171 Effects of desipramine on clinical liver function tests. Am J Psychiatry 1984 0.75
172 Serotonergic function during lithium augmentation of refractory depression. Psychopharmacology (Berl) 1992 0.75
173 Use of yohimbine to counteract nortriptyline-induced orthostatic hypotension. J Clin Psychopharmacol 1989 0.75
174 Baclofen-assisted detoxification from opiates. A pilot study. J Subst Abuse Treat 1992 0.75